Glimprix-M2 Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 50mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle cells. The synergistic action of these two agents provides effective glycemic control in patients inadequately managed by diet and exercise alone. Glimprix-M2 is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia, particularly due to the sulfonylurea component. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Glimprix-M2 should be used under medical supervision to optimize efficacy and minimize potential risks.